Adavosertib (MK-1775)
别名: AZD1775
目录号:S1525 Purity: 99.99%
Adavosertib (MK-1775, AZD1775)是一种有效的,高选择性Wee1抑制剂,无细胞试验中IC50为5.2 nM;阻碍G2期DNA损伤检验点。Phase 2。
CAS: 955365-80-7
客户使用Selleck的Adavosertib (MK-1775)发表文献218篇
- Science, 2024 384(6700):eadk0775
- Nat Biomed Eng, 2024 10.1038/s41551-024-01273-9
- Cell, 2023 186(14):2977-2994.e23
- Nature, 2022 604(7907):749-756
- Cell, 2022 185(16):2988-3007.e20
- Cell, 2021 184(25):6119-6137.e26
- Mol Cancer, 2021 20(1):97
- Cancer Cell, 2020 15 pii: S1535-6108(20)30164-1
- Nat Med, 2019 25(5):838-849
- Cancer Cell, 2019 35(3):519-533
- Cancer Cell, 2019 35(5):752-766
- Cell, 2018 173(1):104-116
- J Hematol Oncol, 2017 10(1):77
- Blood, 2017 130(24):2631-2641
- Cell, 2014 157(3):565-79
- J Hematol Oncol, 2014 7(1):53
- J Thorac Oncol, 2014 9(7):965-73
- Cell, 2013 21;155(5):1088-103.
- Nat Commun, 2024 15(1):2089
- EMBO J, 2024 43(7):1301-1324
- Br J Cancer, 2024 10.1038/s41416-024-02745-0
- Cell Rep, 2024 43(8):114606
- Cell Rep, 2024 43(7):114388
- Life Sci Alliance, 2024 7(5)e202302469
- PLoS One, 2024 19(6):e0304914
- Cancer Biol Ther, 2024 25(1):2421584
- Cancer Biomark, 2024 40(3-4):297-317
- Ren Fail, 2024 46(2):2365408
- Nat Struct Mol Biol, 2023 10.1038/s41594-023-01045-0
- Nat Commun, 2023 14(1):6332
- Nat Commun, 2023 14(1):6088
- EMBO Mol Med, 2023 e16863.
- Cancer Lett, 2023 565:216209
- Cell Death Dis, 2023 14(9):638
- EMBO Rep, 2023 24(12):e57585
- Cell Death Discov, 2023 9(1):285
- Cells, 2023 12(11)1471
- Cancer Cell Int, 2023 23(1):128
- iScience, 2023 10.1016/j.isci.2023.108169
- iScience, 2023 26(1):105806
- Mol Ther Oncolytics, 2023 30:286-300
- Cancers -Basel), 2023 15(19)4772
- Invest Ophthalmol Vis Sci, 2023 64(2):6
- Oncol Rep, 2023 50(3)166
- Oncol Rep, 2023 49(6)125
- Radiat Oncol, 2023 18(1):19
- Cancer Chemother Pharmacol, 2023 92(1):57-69
- Res Sq, 2023 10.21203/rs.3.rs-3314138/v1
- Genes Cancer, 2023 14:56-76
- bioRxiv, 2023 2023.03.27.534412
- Cell Rep Methods, 2023 3(10):100599
- Clin Transl Radiat Oncol, 2023 41:100630
- NAR Cancer, 2023 5(1):zcac045
- Mol Cell, 2022 82(18):3350-3365.e7
- J Clin Invest, 2022 e161544
- J Exp Med, 2022 219(1)e20210789
- Adv Sci (Weinh), 2022 e2105469
- EMBO J, 2022 41(9):e110145
- Cancer Res, 2022 82(21):3950-3961
- Acta Biomater, 2022 S1742-7061(22)00824-8
- Int J Biol Sci, 2022 18(3):1188-1210
- Cell Rep, 2022 39(7):110814
- Cell Rep, 2022 39(5):110789
- Cell Rep, 2022 41(11):111836
- Cell Rep, 2022 38(3):110261
- Breast Cancer Res, 2022 24(1):41
- Cancers (Basel), 2022 14(3)738
- Cancers -Basel, 2022 14-174288
- Front Oncol, 2022 12:954430
- Front Oncol, 2022 12:901132
- Dis Model Mech, 2022 15-2dmm049004
- Sci Adv, 2022 8(5):eabk0221
- Neuro Oncol, 2021 noab197
- Cell Death Differ, 2021 10.1038/s41418-020-00733-4
- Leukemia, 2021 10.1038/s41375-021-01361-8
- J Exp Clin Cancer Res, 2021 40(1):315
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Death Dis, 2021 12(7):683
- Cell Rep, 2021 34(11):108870
- Cell Rep, 2021 34(9):108808
- Br J Cancer, 2021 10.1038/s41416-021-01441-7
- Int J Radiat Oncol Biol Phys, 2021 S0360-3016(21)00361-8
- Biochem Pharmacol, 2021 188:114494
- Cancer Sci, 2021 112(11):4444-4456
- Int J Mol Sci, 2021 22(13)6943
- FEBS J, 2021 10.1111/febs.15747
- Cancers (Basel), 2021 13(14)3487
- J Biol Chem, 2021 S0021-9258(21)01141-8
- Front Oncol, 2021 11:681530
- Front Oncol, 2021 11:683688
- Sci Rep, 2021 11(1):20338
- Cancer Res Treat, 2021 10.4143/crt.2021.320
- Life Sci Alliance, 2021 4(3)e202000980
- Int J Biochem Cell Biol, 2021 137:106028
- Endocr Relat Cancer, 2021 28(5):311-324
- Sci Adv, 2021 7(7)eabd2645
- Mol Biomed, 2021 2(1):19
- Clin Cancer Res, 2020 27 pii: clincanres
- Haematologica, 2020 12;haematol.2019.233445
- Cancer Lett, 2020 472:119-131
- Cell Rep, 2020 32(2):107901
- Cell Rep, 2020 33(9):108449
- JCI Insight, 2020 143474
- Mol Oncol, 2020 10.1002/1878-0261.12882
- Br J Haematol, 2020 21
- Cancer Cell Int, 2020 20:253
- Int J Mol Sci, 2020 18;21(8):2825
- FEBS J, 2020 10.1111/febs.15280
- J Cell Mol Med, 2020 27
- Am J Cancer Res, 2020 10(1):148-163
- Am J Cancer Res, 2020 1;10(3):908-924
- Cancers (Basel), 2020 12(6):1503
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-19-0507
- Ther Adv Med Oncol, 2020 12:1758835920974201
- J Neurooncol, 2020 10.1007
- Diagnostics (Basel), 2020 10(2)
- Ther Adv Hematol, 2020 11:2040620719898373
- Sci Adv, 2020 6(24):eaaz7808
- Nat Commun, 2019 10(1):2189
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0775
- Clin Cancer Res, 2019 25(11):3430-3442
- Clin Cancer Res, 2019 25(7):2290-2304
- Leukemia, 2019 10.1038/s41375-019-0456-2
- Leukemia, 2019 10.1038/s41375-019-0677-4
- J Exp Clin Cancer Res, 2019 38(1):463
- Cancer Res, 2019 10.1158/0008-5472.CAN-18-3374
- Haematologica, 2019 104(11):2225-2240
- Int J Biol Sci, 2019 15(9):1942-1954
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.10.013
- J Cell Biol, 2019 218(5):1531-1552
- Elife, 2019 e46902
- Blood Adv, 2019 3(7):1185-1196
- Gastric Cancer, 2019 10.1007/s10120-019-00977-1
- Oncoimmunology, 2019 8(11):e1638207
- Eur J Med Chem, 2019 161:479-492
- Cells, 2019 8(2)
- Mol Cancer Ther, 2019 18(8):1439-1450
- Mol Cancer Ther, 2019 10.1158/1535-7163.MCT-19-0474
- Front Pharmacol, 2019 10:864
- J Virol, 2019 93(14)
- Cancers (Basel), 2019 11(11)
- Cancers (Basel), 2019 11(6)
- Sci Rep, 2019
- Sci Rep, 2019 9(1):6161
- PLoS One, 2019 14(2):e0212210
- PLoS One, 2019 14(11):e0221288
- Exp Cell Res, 2019 111720
- Hum Mol Genet, 2019 28(5):842-857
- Biochem Biophys Res Commun, 2019 519(3):597-604
- Biochem Biophys Res Commun, 2019 10.1016/j.bbrc.2019.10.124
- Nat Commun, 2018 9(1):3982
- Nucleic Acids Res, 2018 46(10):5109-5124
- J Exp Clin Cancer Res, 2018 37(1):129
- Cancer Res, 2018 78(11):3054-3066
- J Immunother Cancer, 2018 6(1):59
- Cancer Lett, 2018 430:34-46
- Curr Biol, 2018 28(23):3824-3832
- Int J Biol Sci, 2018 14(10):1221-1231
- Cell Rep, 2018 22(12):3206-3216
- Cells, 2018 7(9)
- Cancers (Basel), 2018 10(5)
- Front Oncol, 2018 8:143
- Sci Rep, 2018 8(1):948
- BMC Cancer, 2018 18(1):922
- PLoS One, 2018 13(2):e0193098
- Biomed Res Int, 2018 2018:5813292
- Bioorg Med Chem, 2018 26(14):4014-4024
- Oncol Lett, 2018 16(4):5473-5481
- SSRN, 2018 10.2139/ssrn.3188455
- Genes Dev, 2017 31(3):318-332
- Br J Cancer, 2017 117(1):113-123
- Aging Cell, 2017 16(3):575-584
- J Med Chem, 2017 60(18):7863-7875
- Mol Cancer Ther, 2017 16(9):2022-2034
- Oncotarget, 2017 8(43):73705-73722
- Oncotarget, 2017 8(7):10966-10979
- Oncotarget, 2017 8(55):94780-94792
- Oncotarget, 2017 8(27):44295-44311
- Oncotarget, 2017 8(67):111026-111040
- Oncotarget, 2017 8(35):59476-59491
- Oncotarget, 2017 8(63):106352-106368
- Sci Rep, 2017 7:43517
- J Chromatogr B Analyt Technol Biomed Life Sci, 2017 1044-1045:70-76
- Clin Cancer Res, 2016 22(17):4440-51
- Mol Cancer Ther, 2016 15(6):1332-43
- Mol Cancer Ther, 2016 15(7):1669-81
- Oncotarget, 2016 7(27):41320-41335
- Oncotarget, 2016 7(31):49902-49916
- Oncotarget, 2016 7(23):34785-99
- Stem Cells, 2016 34(7):1765-75
- Sci Rep, 2016 6:33323
- J Cell Sci, 2016 129(16):3167-77
- BMC Cancer, 2016 16:678
- Genetics, 2016 204(2):807-819
- Tumour Biol, 2016 10.1007/s13277-016-5081-3
- Genes Dev, 2015 29(5):555-66
- Oncotarget, 2015 6(15):13072-87
- Oncotarget, 2015 6(25):21074-84
- Sci Rep, 2015 5:16991
- Cell Cycle, 2015 14(7):1070-81
- BMC Cancer, 2015 15:462
- Cancer Biol Ther, 2015 16(12):1784-93
- Radiat Res, 2015 184(6):660-9
- Pediatr Blood Cancer, 2015 62(1):52-9
- Genes Cancer, 2015 6(5-6):184-213
- Clin Cancer Res, 2014 20(16):4274-88
- Genes Dev, 2014 28(14):1578-91
- Cancer Lett, 2014 356(2 Pt B):656-68
- J Cell Biol, 2014 206(7):843-53
- Oncotarget, 2014 5(21):10546-57
- J Cell Mol Med, 2014 18(1):143-55
- Cell Cycle, 2014 13(2):303-14
- Pediatr Blood Cancer, 2014 61(10):1767-73
- Expert Opin Drug Metab Toxicol, 2013 9(2):215-24
- PLoS One, 2013 8(3):e57523
- Obstet Gynecol Int, 2013 2013:828165
- Mol Cancer Ther, 2012 11(1):174-82
- Pediatr Surg Int, 2012 28(6):579-89
化学信息&溶解度
分子量 | 500.6 |
分子式 | C27H32N8O2 |
CAS号 | 955365-80-7 |
Smiles | CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 10 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 199.76 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:12mg/ml
(23.97mM)
操作示例:以 1 mL 工作液为例,取 50 μL 240 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
|
5%DMSO
95% Corn oil
浓度:6mg/ml
(11.99mM)
操作示例:以 1 mL 工作液为例,取 50 μL 120 mg/mL 的澄清 DMSO 储备液加到 950 μL玉米油中,混合均匀。工作液请现配现用!
|
|
5%DMSO
40%PEG 300
5%Tween80
50% ddH2O
浓度:5mg/ml
(9.99mM)
操作示例:以 1 mL 工作液为例,取 50 μL 100 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀使其澄清;向上述体系中加入50 μL Tween-80,混合均匀使其澄清;然后继续加入 500 μLddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。